oral semaglutide weight loss real-world study use of versus subcutaneous in a cohort of type 2 diabetic patients: which option to which patient? | Journal of Endocrinological Investigation RWD study: Mounjaro more effective

O 1 agonizm GLP-1R

Meanwhile, multiple ongoing studies explore its neuroprotective potential for Alzheimer's disease and ischemic stroke, relying on anti-inflammatory and nerve-cell anti-apoptosis properties to slow neurodegenerative progression

Whats more, how would it impact me on the bike

Maintaining this loss requires continued medication

Rare but serious risks include: Pancreatitis : Severe abdominal pain should prompt immediate medical attention Gallbladder problems : Rapid weight loss can increase gallstone risk Diabetic retinopathy complications : In people with existing eye disease, rapid glucose improvement may temporarily worsen retinopathy, particularly with semaglutide [14] [15] Hypoglycaemia : Low blood sugar is uncommon with GLP-1 agonists alone but can occur if combined with insulin or sulphonylureas [17] [18] GLP-1 agonists are not recognised to directly cause dangerous blood pressure drops (hypotension) in most patients

La Cava A, Matarese G